Urokinase versus Recombinant Tissue Plasminogen Activator in Thrombosed Central Venous Catheters:

Summary

Fifty dysfunctional central venous catheters proven radiographically to be occluded by thrombus were blindly randomized to be injected with either 2 mg recombinant tissue plasminogen activator (t-PA) or 10,000 units of urokinase (UK) and allowed to incubate for 2 h. A second dose was allowed if catheter function was not restored with the first injection. Repeat radiograph contrast injection was done when catheter function was restored or after 2 doses of study drug were administered, whichever occurred first. Thirteen of 22 catheters randomized to UK had full function restored compared to 25 of 28 randomized to t-PA (p = 0.013). Radiographic contrast injection showed 7 catheters randomized to UK had complete resolution of the thrombus compared to 17 randomized to t-PA (p = 0.042). Four catheters randomized to UK had complete resolution of the thrombus after a single dose compared to 13 randomized to t-PA (p = 0.036). A novel dose of 2 mg of t-PA restored catheter function more reliably and dissolved thrombi faster than twice the standard, FDA-approved dose of UK

• References

• 1 Raaf JH. Results from the use of 826 vascular access devices in cancer patients. Cancer 1985; 55: 1312-1321
• 2 Rubin RN. Local instillation of small doses of streptokinase for treatment of thrombotic occlusions of long-term access catheters. J Clin Oncol 1983; 1: 572-573
• 3 Tschirhart JM, Rao MK. Mechanism and management of persistent withdrawal occlusion. Am Surg 1988; 54: 326-328
• 4 Lokich JJ, Both A, Benotti P. Complications and management of implanted central venous catheters. J Clin Oncol 1985; 3: 710-717
• 5 Brismar B, Hardstedt C, Malmborg A-S. Bacteriology and phlebography in catheterization for parenteral nutrition. Acta Chir Scand 1980; 146: 115-119
• 6 Grant JP. Catheter access. In: Clinical Nutrition, volume 2, Parenteral Nutrition Rombeau JL, Caldwell MD. eds. Philadelphia: W. B. Saunder and Company; 1989: 306-315
• 7 Blacklock HA, Hill RS, Clark AG. Use of modified subcutaneous right atrial catheter for venous access in leukemic patients. Lancet 1980; 1: 993-994
• 8 Hurtibise MR, Bottino JC, Lawson M, McCredie KM. Restoring patency of occluded central venous catheters. Arch Surg 1980; 1115: 212-213
• 9 Lawson M, Bottino JC, Hurtibise MR, McCredie KB. The use of urokinase to restore patency of occluded central venous catheters. Am J Intraven Ther Clin Nutr 1982; 9: 29-32
• 10 Lund GB, Lieberman RP, Haire WE. Central venous catheters. Sem Intervent Radiol 1989; 6: 162-175
• 11 Johnsdn RL, Lieberman RP, Kaplan PA, Haire WD. Silicone rubber catheter venography using standard angiographic techniques. Cardiovasc Intervent Radiol 1988; 11: 45-49
• 12 Cassidy FP, Zajko AB, Bron KM, Reilly JJ, Peitzman AB, Steed DL. Non-infectious complications of long-term central venous catheters: radiologic evaluation and management. AJR 1987; 149: 671-675
• 13 Monturo CA, Dickerson RN, Mullen JL. Efficacy of thrombolytic therapy for occlusion of long-term catheters. JPEN 1990; 14: 312-314
• 14 Collen D, Lijnen HR. Tissue-type plasminogen activator: mechanism of action and thrombolytic properties. Haemostasis 1986; (Suppl. 16) 3: 25-32
• 15 Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. JPEN 1990; 14: 310-311
• 16 Haire WD, Lieberman RP. Thrombosed central venous catheters: restoring function with a 6-h urokinase infusion after failure of bolus urokinase. JPEN 1992; 16: 129-132
• 17 Haire WD, Lieberman RP, Lund GB, Edney J, Wieczorek BM. Obstructed central venous catheter: restoring function with a 12-hour infusion of low-dose urokinase. Cancer 1990; 66: 2279-2285
• 18 Haire WD, Lieberman RP, Schmit-Pokorny K, Kessinger A. Urokinase infusion restores function of thrombotically occluded inferior vena cava apheresis catheters refractory to bolus urokinase therapy. Transfus Sci 1991; 12: 311-316